Evidence map›Paper›PMID 40403153›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes.

Naomi Hannaway, Angeliki Zarkali, Rohan Bhome, Ivelina Dobreva, George E C Thomas, Elena Veleva, Irene Gorostiaga Belio, Katie Tucker, Amanda Heslegrave, Henrik Zetterberg and 1 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. The clinical translation of blood biomarkers for Alzheimer's disease: Timing and challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Reply: Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Naomi HannawayDementia Research Centre, UCL Institute of Neurology, London, UK.ORCID 0000-0001-8608-7757
Angeliki ZarkaliDementia Research Centre, UCL Institute of Neurology, London, UK.
Rohan BhomeDementia Research Centre, UCL Institute of Neurology, London, UK.
Ivelina DobrevaDementia Research Centre, UCL Institute of Neurology, London, UK.
George E C ThomasDementia Research Centre, UCL Institute of Neurology, London, UK.
Elena VelevaUnited Kingdom Dementia Research Institute, UCL, London, UK.
Irene Gorostiaga BelioDementia Research Centre, UCL Institute of Neurology, London, UK.
Katie TuckerDementia Research Centre, UCL Institute of Neurology, London, UK.
Amanda HeslegraveUnited Kingdom Dementia Research Institute, UCL, London, UK.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Rimona S WeilDementia Research Centre, UCL Institute of Neurology, London, UK.

Funding

Alzheimer's Research UK Clinical Research Fellowship 2018B-001Hackett, Harris & Hopkins familyRosetrees Trust PGS22-100111UCLH Biomedical Research CentreWellcome Trust 225263Z/22/Z
6 · The paper itself

Abstract

introductionDespite ongoing debate about whether Parkinson's disease (PD) dementia (PDD) and dementia with Lewy bodies (DLB) are separable diseases or a single Lewy body dementia (LBD) spectrum, there are limited investigations of differences between these conditions.

methodsWe used fixel-based diffusion magnetic resonance imaging and plasma measures to examine white matter integrity and burden of amyloid pathology (using phosphorylated tau-217 [p-tau217]) in 47 patients with DLB, 21 with PDD, 29 with PD, and 23 age-matched controls.

resultsWe show reduced fiber cross-section in LBD versus PD, and increased concentrations of plasma neurofilament light chain and p-tau217; with p-tau217 and fiber cross-section associated with cognition. Fiber density was reduced in PDD versus DLB, but neither plasma measures nor fiber cross-section differed between LBD subtypes. DISCUSSION: Our findings suggest that the presence of dementia in LBD is associated with poorer white matter macrostructure and may relate to pathological protein accumulation. Conversely, differences between DLB and PDD may be driven by other factors. HIGHLIGHTS: Plasma neurofilament light and phosphorylated tau-217 were increased in Lewy body dementia (LBD) relative to Parkinson's disease (PD) and controls. Magnetic resonance imaging (MRI) white matter macrostructure (fiber cross-section) was reduced in LBD relative to PD. In contrast, MRI white matter microstructure (fiber density) was reduced in PD dementia compared to dementia with Lewy bodies. Differences between dementia with Lewy bodies and PD dementia were distinct compared with those between LBD and Parkinson's with normal cognition. Our findings suggest that dementia with Lewy bodies and Parkinson's dementia differ in underlying processes distinct from those driving dementia.

Indexed as

Lewy Body DiseaseNeuroimagingParkinson Diseasetau ProteinsWhite MatterAgedAged, 80 and overBiomarkersCase-Control StudiesDiffusion Magnetic Resonance ImagingFemaleHumansMaleMiddle AgedObservational Studies as TopicPhosphorylationBiomarkerstau ProteinsbiomarkersimagingLewy body dementiaMRIParkinson's disease dementiaplasma

Identifiers

PMID40403153
PMCPMC12097529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.